Abstract
Objectives: Previously we showed the following about Heat Shock Protein 27 (HSP27): i) Increasing serum levels either via over-expression (HSP27o/e mice), bone marrow transplantation or recombinant HSP27 (rHSP27) injection attenuate de novo atherogenesis, and ii) low serum levels represent a novel biomarker for human atherosclerotic events (MI, CVA, Death). We now test the ability of rHSP27 to modulate the progression of established atherosclerotic lesions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
